More data is needed from AstraZeneca’s Covid vaccine trials beyond what was presented in a press release, experts from the WHO and Oxford University said.
More data will be needed from AstraZeneca’s coronavirus vaccine trials to determine the drug’s safety and efficacy following concerns from experts in the U.S., scientists from the University of Oxford and the World Health Organizations said on Friday. «There’s always a problem in announcing scientific results by press release, and that is that you don’t have all the data out there and people aren’t able to really look and think about the data properly,» Sir John Bell, the Regius professor of medicine at Oxford University, told CNBC’s «Closing Bell» on Friday. Shares of AstraZeneca dipped this week after the company announced interim results from its coronavirus vaccine trials on Monday. The British pharmaceutical giant said its vaccine, which it’s developing alongside Oxford, was 70% effective after it combined results from two different dosing regimes. One smaller group of people, all under the age of 55, received an unintentionally lower dose of the vaccine followed by a full dose, and a larger group of people received two full doses of the vaccine.
